MNPRライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:04):

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States...

Stats
本日の出来高	8 092.00
平均出来高	5.50M
時価総額	11.34M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.170 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.070
ATR14	$0.00600 (0.92%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-31	Cittadine Andrew	Sell	8 952	Restricted Stock Units
2024-03-31	Cittadine Andrew	Buy	8 952	Common Stock
2024-03-31	Cittadine Andrew	Sell	3 098	Common Stock
2024-03-31	Tsuchimoto Kim R	Sell	9 956	Restricted Stock Units
2024-03-31	Tsuchimoto Kim R	Buy	9 956	Common Stock

INSIDER POWER
37.13
Last 100 transactions
Buy: 1 127 208 \| Sell: 341 037

ボリューム相関

長: -0.05 (neutral)

短: -0.12 (neutral)

Signal:(46.501) Neutral

Monopar Therapeutics Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Monopar Therapeutics Inc 相関 - 通貨/商品

0.05
( neutral )

0.31
( neutral )

0.00
( neutral )

0.25
( neutral )

Monopar Therapeutics Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.610

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.610

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.830

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Monopar Therapeutics Inc

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.